The pathobiology and treatment of Hodgkin lymphoma. Where do we go from Gianni Bonadonna's lesson?

Research output: Contribution to journalReview articlepeer-review

Abstract

This article reviews the evolution of the diagnosis and treatment of Hodgkin lymphoma (HL) since its discovery in 1832. The morphological, phenotypic and molecular characteristics of both nodular lymphocyte-predominant HL and classical HL are revised in the light of recent molecular information and possible impact on the identification of risk groups as well as the use of targeted therapies. The seminal contribution of Gianni Bonadonna to developing new treatment strategies for both advanced and early-stage HL is highlighted.

Original languageEnglish
Pages (from-to)101-113
Number of pages13
JournalTumori
Volume103
Issue number2
DOIs
Publication statusPublished - Mar 1 2017

Keywords

  • ABVD
  • Brentuximab vedotin
  • Checkpoint inhibitors
  • Histology
  • Hodgkin lymphoma
  • Molecular biology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The pathobiology and treatment of Hodgkin lymphoma. Where do we go from Gianni Bonadonna's lesson?'. Together they form a unique fingerprint.

Cite this